Frame 1000003625
Frame 1000003626

AI-guided life sciences intelligence for better BD&L decisions

Find licensing opportunities, partners and investors faster. Ask in plain language and get structured answers from curated, sourced life sciences data.

bdl

From natural language query to structured BD&L output

aiworkspace

Sourced insights from analyst reports and financial models.

Some of our clients

Our Platform

Two AI-guided workflows.
One life sciences intelligence platform.

Biotechgate combines deep life sciences data with AI-guided search and research workflows. Whether you're identifying licensing opportunities or conducting due diligence, you get to the insight that matters without spending hours piecing information together.

BD&L Intelligence

Search in plain language across companies, assets, licensing opportunities, deals, trials, financing rounds, management contacts and partnering interests. Just describe what you're looking for and Biotechgate translates it into precise, structured results. No complex query language. No dead ends.

Explore BD&L Intelligence

AI Research Workspace

Ask questions across curated analyst reports and financial models to support due diligence, valuation, pipeline assessment and market research. Get sourced insights from trusted research content, so your team can spend less time reviewing documents and more time deciding what matters.

Explore AI Research Workspace
Our Coverage

Structured data and
research intelligence behind every AI-guided workflow.

Biotechgate's intelligence layer connects curated company, asset, clinical, financial, deal and contact data - giving your team the structured foundation needed for faster search, analysis and business development decisions.

70K+

Company Profiles

Global life sciences companies with structured business and pipeline data.

385K+

Management Contacts

Executive and functional contacts for outreach, qualification and partnering.

42K+

Licensing-ready Assets

Assets and technologies with development phase, indication and licensing status.

1M+

Clinical Trials

Trial activity to support pipeline, competitor and market analysis.

250K+

Reports & Forecast Models

Curated analyst reports and financial models for research, valuation and due diligence.

48K+

License Agreements

Deal terms, territories, payment structures and original contract references.

Curated, continuously updated life science intelligence - combining structured data, expert review and source-based research content.

baner overview

Dec 7 – Dec 11, 2026

Free registration

BIOTECHGATE DIGITAL PARTNERING

Virtual business development & licensing event

Join five days of digital partnering, workshops and networking sessions. Establish new global connections thanks to pre-arranged one-on-one Zoom meetings.

What our clients say

“Since I started to use Biotechgate my prospective activities have become far less time-consuming and the collected information much more up-to-date which is most satisfactory.”

Linda Slipko

Business Development Manager at GreenLight Clinical

We have used Biotechgate for a year now and we have been very satisfied with the system so far. It has provided us with an enormous amount of business intelligence of our marketplace.

Chris Huiskamp

Managing Partner at Sourcia

Liftstream was compelled to subscribe to Biotechgate as it is really the only international database of the life sciences sector which is frequently updated by those who are listed on it. This ensures that you can access and retrieve information based on geography, therapy, modality, management or any other category of information which is important to your search.

Karl Simpson

CEO at Liftstream

Upcoming Conferences

 

19 November 2026
19 November 2026

Agile Leaders Forum on Dealmaking & Investment Strategies

London, United Kingdom
A thought leadership workshop for Business & Research Leaders from life sciences innovation companies and investors Are you a business leader of a Life Science Innovation company or investor? Are you interested in discussing current dealmaking and investment strategies that are working? Do want to learn more about other people's experiences, or share your thoughts and queries around investment & dealmaking? Are you looking to learn from, and meet with, your peers and experienced industry professionals and seasoned investors? What are the Dealmaking & Investment Strategies that are working? The life sciences and biotech sector is currently grappling with a range of investment challenges shaped by regulatory pressures, evolving market dynamics, and shifting public sentiment. As the industry strives to recover from the pandemic’s disruption, deal-making has become more cautious and complex, reflecting the demand for robust compliance and transparency. One significant challenge is the increased regulatory scrutiny following COVID-19. Investors are now prioritizing companies with clear pathways to regulatory approval and validated clinical data. This trend influences venture capital flows, as investors seek to minimize risk by backing firms with established compliance measures. Smaller biotech companies, in particular, face hurdles in securing funding, as they often lack the resources to navigate the intricate regulatory landscape effectively. Moreover, public perception regarding drug pricing and access is steering investment decisions. Investors are more inclined to support companies that align their missions with social responsibility and ethical practices. This societal lens encourages firms to develop narratives that emphasize not only financial viability but also positive community impact, a factor that is increasingly crucial in attracting committed investors. To address these challenges, strategic partnerships are emerging as a vital solution. Collaborations between small biotech startups and larger pharmaceutical firms can enhance credibility and access to resources, providing a safety net for navigating regulatory complexities. Additionally, the use of non-dilutive funding—such as grants and government contracts—has gained traction, allowing companies to focus on long-term innovations without immediate financial pressures.In this evolving landscape, investment strategies that embrace transparency, collaboration, and ethical considerations will be pivotal. As the life sciences sector adapts, innovative approaches will unlock new opportunities for growth, ensuring a sustainable path forward for the future of healthcare. Green-Shoots? We will explore what is happening in Europe and the US with experts that know the activity in the financial marketplace. We will have Bill Hicks with us from Mintz in Boston, US along with James Fry from Mills & Reeve who has his finger on the pulse regarding the UK and EU markets, along with other experts.
Read more
20 November 2026
20 November 2026

Pharma-Biotech Product & Company Valuation Workshop

Online
In the high-stakes world of pharma and biotech, traditional valuation methods often fail to capture the realities of the industry. Unique factors such as high R&D attrition rates, extended investment cycles, and complex IP landscapes demand a specialised approach. This course provides a practical introduction to product and company valuation tailored specifically for the pharma and biotech sectors. You will learn the core concepts, tools, and techniques essential for financing rounds and investment decisions, as well as M&A, licensing deals and partnerships, strategic development planning, and portfolio optimisation.
Read more
24 November 2026
25 November 2026

BioPharma Deals Conference 2026

Munich, Germany
BioPharma Deals Conference 2026 is a focused gathering for the biopharma dealmaking community, bringing together senior professionals from biotech and pharmaceutical companies, investors, advisors, and other key industry stakeholders to explore opportunities across business development, licensing, strategic partnerships, investment, M&A, and co-development. The event will feature: High-level networking with senior industry professionals Curated one-to-one partnering meetings Discussions on business development, licensing, investment, and strategic transactions Opportunities to connect with biotech innovators, pharma leaders, investors, and advisors A focused platform for developing meaningful business and dealmaking connections
Read more
24 November 2026
25 November 2026

Biotech Outsourcing Strategies Manchester 2026

Manchester, United Kingdom
Biotech Outsourcing Strategies Events bring together stakeholders in R&D outsourcing to share experience, build existing outsourcing partnerships and forge new buyer/supplier business relationships. BOS is an event where business gets done and where you can be confident of high quality interactions with potential business partners. The BOS Events story began in 2006 with our 1st event hosted in Sheffield, UK. Our event format has been refined over the years and now consists of 4 key components; Programme; Partnering; Exhibition and Informal Networking You will receive a warm welcome from the Bio2Business team in the vibrant and buzzing City of Manchester!
Delegates from Venture Valuation and Biotechgate will attend the event.
Read more

See how Biotechgate can enhance
your business development